The 8; 21 translocation in leukemogenesis

LF Peterson, DE Zhang - Oncogene, 2004 - nature.com
A common chromosomal translocation in acute myeloid leukemia (AML) involves the AML1
(acute myeloid leukemia 1, also called RUNX1, core binding factor protein (CBFα), and …

Acute myeloid leukemia with the 8q22; 21q22 translocation: secondary mutational events and alternative t (8; 21) transcripts

LF Peterson, A Boyapati, EY Ahn… - Blood, The Journal …, 2007 - ashpublications.org
Nonrandom and somatically acquired chromosomal translocations can be identified in
nearly 50% of human acute myeloid leukemias. One common chromosomal translocation in …

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis

V Kapuria, LF Peterson, D Fang, WG Bornmann… - Cancer research, 2010 - AACR
Recent evidence suggests that several deubiquitinases (DUB) are overexpressed or
activated in tumor cells and many contribute to the transformed phenotype. Agents with DUB …

Protein ISGylation modulates the JAK-STAT signaling pathway

OA Malakhova, M Yan, MP Malakhov… - Genes & …, 2003 - genesdev.cshlp.org
ISG15 is one of the most strongly induced genes upon viral infection, type I interferon (IFN)
stimulation, and lipopolysaccharide (LPS) stimulation. Here we report that mice lacking …

A previously unidentified alternatively spliced isoform of t (8; 21) transcript promotes leukemogenesis

M Yan, E Kanbe, LF Peterson, A Boyapati, Y Miao… - Nature medicine, 2006 - nature.com
Abstract The t (8; 21)(q22; q22) translocation is one of the most common genetic
abnormalities in acute myeloid leukemia (AML), identified in 15% of all cases of AML …

[HTML][HTML] Bimekizumab versus secukinumab in plaque psoriasis

K Reich, RB Warren, M Lebwohl… - … England Journal of …, 2021 - Mass Medical Soc
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both
interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared …

[HTML][HTML] Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized …

KA Papp, JF Merola, AB Gottlieb, CEM Griffiths… - Journal of the American …, 2018 - Elsevier
Background Neutralizing interleukin (IL) 17F in addition to IL-17A might provide a more
complete and specific approach to inhibiting inflammation. Objective Assess the efficacy and …

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE …

JS Smolen, GR Burmester, B Combe, JR Curtis, S Hall… - The Lancet, 2016 - thelancet.com
Background To date, head-to-head trials comparing the efficacy and safety of biological
disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in …

[HTML][HTML] Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia

S Klossowski, H Miao, K Kempinska… - The Journal of …, 2020 - Am Soc Clin Investig
The protein-protein interaction between menin and mixed lineage leukemia 1 (MLL1) plays
a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in …

[HTML][HTML] Expanding the diversity of mycobacteriophages: insights into genome architecture and evolution

WH Pope, D Jacobs-Sera, DA Russell, CL Peebles… - PloS one, 2011 - journals.plos.org
Mycobacteriophages are viruses that infect mycobacterial hosts such as Mycobacterium
smegmatis and Mycobacterium tuberculosis. All mycobacteriophages characterized to date …